1. Academic Validation
  2. CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2

CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2

  • CRISPR J. 2025 Feb;8(1):60-70. doi: 10.1089/crispr.2024.0079.
Gongbo Guo 1 Morgan Moser 1 Lincoln Chifamba 1 Dominic Julian 1 Samantha Teierle 2 Prajwal Rajappa 1 3 Cecelia Miller 4 Mark E Hester 1 3 5
Affiliations

Affiliations

  • 1 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • 2 Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
  • 3 Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • 4 Department of Pathology, The Ohio State University, Columbus, Ohio, USA.
  • 5 Department of Neuroscience, The Ohio State University, Columbus, Ohio, USA.
Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the TSC1 or TSC2 genes. Though TSC causes the formation of nonmalignant tumors throughout multiple organs, the most frequent causes of mortality and morbidity are due to neurological complications. In two-thirds of cases, TSC occurs sporadically and TSC2 pathogenic variants are approximately three times more prevalent than TSC1 pathogenic variants. Here, we utilized CRISPR-Cas9-mediated homology directed repair in patient induced pluripotent stem cells (iPSCs) to correct two types of TSC2 pathogenic variants generating two isogenic lines. In one line, we corrected a splice acceptor variant (c.2743-1G>A), which causes the skipping of coding exon 23 and subsequent frameshift and introduction of a stop codon in coding exon 25. In the second line, we corrected a missense variant in coding exon 40 within the GTPase-activating protein domain (c.5228G>A, p.R1743Q). The generation of TSC2 patient iPSCs in parallel with their corresponding CRISPR-corrected isogenic lines will be an important tool for disease modeling applications and for developing therapeutics.

Figures
Products